Cisatracurium Besylate (Page 2 of 9)
2.6 Rate Tables for Continuous Infusion
The intravenous infusion rate depends upon the cisatracurium besylate injection concentration, the desired dose, the patient’s weight, and the contribution of the infusion solution to the fluid requirements of the patient. Tables 1 and 2 provide guidelines for the cisatracurium infusion rate, in mL/hour (equivalent to microdrops/minute when 60 microdrops = 1 mL), in concentrations of 0.1 mg/mL or 0.4 mg/mL, respectively.
Drug Delivery Rate (mcg/kg/minute) | |||||
---|---|---|---|---|---|
1 | 1.5 | 2 | 3 | 5 | |
Patient Weight | Infusion Delivery Rate (mL/hour) | ||||
10 kg | 6 | 9 | 12 | 18 | 30 |
45 kg | 27 | 41 | 54 | 81 | 135 |
70 kg | 42 | 63 | 84 | 126 | 210 |
100 kg | 60 | 90 | 120 | 180 | 300 |
Drug Delivery Rate (mcg/kg/minute) | |||||
1 | 1.5 | 2 | 3 | 5 | |
Patient Weight | Infusion Delivery Rate (mL/hour) | ||||
10 kg | 1.5 | 2.3 | 3 | 4.5 | 7.5 |
45 kg | 6.8 | 10.1 | 13.5 | 20.3 | 33.8 |
70 kg | 10.5 | 15.8 | 21 | 31.5 | 52.5 |
100 kg | 15 | 22.5 | 30 | 45 | 75 |
2.7 Preparation of Cisatracurium Besylate Injection
Visually inspect cisatracurium besylate injection for particulate matter and discoloration prior to administration. If a cisatracurium besylate injection solution is cloudy or contains visible particulates, do not use cisatracurium besylate injection. Cisatracurium besylate injection is a colorless to slightly yellow or greenish-yellow solution.
Cisatracurium besylate injection may be diluted to 0.1 mg/mL in the following solutions:
- 5% Dextrose Injection, USP
- 0.9% Sodium Chloride Injection, USP, or
- 5% Dextrose and 0.9% Sodium Chloride Injection, USP
Store these diluted cisatracurium besylate injection solutions either in a refrigerator or at room temperature for 24 hours without significant loss of potency.
Cisatracurium besylate injection also may be diluted to 0.1 mg/mL or 0.2 mg/mL in the following solution:
- Lactated Ringer’s and 5% Dextrose Injection
Store this diluted cisatracurium besylate injection solution under refrigeration for no more than 24 hours.
Do not dilute cisatracurium besylate injection in Lactated Ringer’s Injection, USP due to chemical instability.
2.8 Drug Compatibility
Cisatracurium besylate injection is compatible and may be administered with the following solutions through Y-site administration:
- 5% Dextrose Injection, USP
- 0.9% Sodium Chloride Injection, USP
- 5% Dextrose and 0.9% Sodium Chloride Injection, USP
- Sufentanil Citrate Injection, diluted as directed
- Alfentanil Hydrochloride Injection, diluted as directed
- Fentanyl Citrate Injection, diluted as directed
- Midazolam Hydrochloride Injection, diluted as directed
- Droperidol Injection, diluted as directed
Cisatracurium besylate injection is acidic (pH = 3.25 to 3.65) and may not be compatible with alkaline solution having a pH greater than 8.5 (e.g., barbiturate solutions). Therefore, do not administer cisatracurium besylate injection and alkaline solutions simultaneously in the same intravenous line.
Cisatracurium besylate injection is not compatible with propofol injection or ketorolac injection for Y-site administration. Compatibility studies with other parenteral products have not been conducted.
3 DOSAGE FORMS AND STRENGTHS
Cisatracurium besylate injection is available as a clear colorless to slightly yellow or greenish-yellow solution in the following strengths:
- 10 mg of cisatracurium per 5 mL (2 mg/mL) in single-dose vials (equivalent to 2.68 mg/mL cisatracurium besylate)
- 20 mg of cisatracurium per 10 mL (2 mg/mL) in multiple-dose vials (equivalent to 2.68 mg/mL cisatracurium besylate) with benzyl alcohol as a preservative.
4 CONTRAINDICATIONS
- Cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. Severe anaphylactic reactions to cisatracurium have been reported [see Warnings and Precautions (5.4)].
- The use of 10 mL cisatracurium besylate injection multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see Warnings and Precautions (5.2) and Use in Specific Populations (8.4)].
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/cisatracurium-besylate-4/page/2/